457
Views
7
CrossRef citations to date
0
Altmetric
Review

A patent review of BRAF inhibitors: 2013-2018

, &
Pages 595-603 | Received 23 Mar 2019, Accepted 03 Jul 2019, Published online: 13 Jul 2019

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Peng-Fei Wang, Han-Yue Qiu, Yun He & Hai-Liang Zhu. (2020) Cyclin-dependent kinase 4/6 inhibitors for cancer therapy: a patent review (2015 – 2019). Expert Opinion on Therapeutic Patents 30:10, pages 795-805.
Read now

Articles from other publishers (6)

Ankit Kumar Singh, Pankaj Sonawane, Adarsh Kumar, Harshwardhan Singh, Vladislav Naumovich, Prateek Pathak, Maria Grishina, Habibullah Khalilullah, Mariusz Jaremko, Abdul-Hamid Emwas, Amita Verma & Pradeep Kumar. (2023) Challenges and Opportunities in the Crusade of BRAF Inhibitors: From 2002 to 2022. ACS Omega 8:31, pages 27819-27844.
Crossref
Rohit Arora, Joannes T.M. Linders, Samia Aci-Sèche, Thomas Verheyen, Erika Van Heerde, Dirk Brehmer, Apirat Chaikuad, Stefan Knapp & Pascal Bonnet. (2023) Design, synthesis and characterisation of a novel type II B-RAF paradox breaker inhibitor. European Journal of Medicinal Chemistry 250, pages 115231.
Crossref
Ankit Kumar Singh, Adarsh Kumar, Suresh Thareja & Pradeep Kumar. (2023) Current Insights into the Role of BRAF Inhibitors in Treatment of Melanoma. Anti-Cancer Agents in Medicinal Chemistry 23:3, pages 278-297.
Crossref
Lizhao Hu, Yuyao Yang, Shuangjia Zheng, Jun Xu, Ting Ran & Hongming Chen. (2021) Kinase Inhibitor Scaffold Hopping with Deep Learning Approaches. Journal of Chemical Information and Modeling 61:10, pages 4900-4912.
Crossref
Nihay Laham-Karam, Gaspar P. Pinto, Antti Poso & Piia Kokkonen. (2020) Transcription and Translation Inhibitors in Cancer Treatment. Frontiers in Chemistry 8.
Crossref
Ufuk Degirmenci, Mei Wang & Jiancheng Hu. (2020) Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy. Cells 9:1, pages 198.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.